Our lead program is for treatment of inflammatory bowel disease (IBD), which is comprised of Crohn’s Disease (CD) and Ulcerative Colitis (UC). Artizan also has a paradigm-changing second program in Parkinson’s Disease.
Gastrointestinal / Immunology
IBD refers to a set of diseases that cause chronic inflammation of the small and/or large intestines with roughly 45% of cases defined as CD and 55% are UC.1 The global prevalence of IBD exceeds 3 million cases, approximately 1.8 million of which are in the United States. CD and UC can occur at any age, but diagnoses are most frequent between the ages of 15 and 35. IBD is a complex condition for which currently available therapies are only moderately effective, many patients fail to achieve a deep, long-lasting remission. While there have been tremendous advances in IBD therapies, approximately 30% of patients are unresponsive to initial biologics therapy and, even among responsive patients, up to 10% stop responding to treatment annually. For more information about IBD, please visit the Crohn’s & Colitis Foundation.
1 Hazel K, O’Connor A. Emerging treatments for inflammatory bowel disease. Ther Adv Chronic Dis. 2020;11:2040622319899297. Published 2020 Feb 5. DOI: 10.1177/2040622319899297
More than 10 million people worldwide are living with PD Parkinson’s disease. (PD) is the second most common neurodegenerative disease in the United States, affecting an estimated 1 million people or ~1% of the entire US population. PD is a neurodegenerative amyloid disorder that causes unintended or uncontrollable movements of the body. While the precise cause of PD is unknown, some cases are thought to occur from a combination of genetics, immunologic, and environmental factors that trigger the disease. Studies have shown that signals from gut microbes are required for neuroinflammatory responses and promote a-synuclein-mediated motor deficits and brain pathology.1 PD has no cure and current treatments help control symptoms, but do not address its root cause. For more information, please visit the Parkinson’s Foundation.
1 Sampson, et al. Gut Microbiota Regulate Motor Deficits and Neuroinflammation in Model of Parkinson’s Disease. Cell.2016;167:1469-1480; DOI: https://doi.org/10.1016/j.cell.2016.11.018